Graft Polymer (UK) PLC has joined forces with the Faculty of Polymer Technology in Slovenia to develop polymer matrices, combining their technological expertise to prepare and test product samples over the course of a year.

Materials provided by Graft will enable the faculty to take part in a number of cornerstone Horizon projects in the European Union.

https://www.proactiveinvestors.co.uk/companies/news/1026033/graft-polymer-targets-innovative-vitrimer-industry-with-latest-collaboration-1026033.html

Graft Polymer (UK) PLC (LSE:GPL) told investors it has inked a new research, development and supply agreement, its third in two months, to work with new partner FORPET BALTIC.

The latest agreement sees the companies working together to research the production of recycled PET, a sustainable and environmentally friendly form of polyethylene terephthalate – the type of plastic used in water bottles, food containers and other packaging.

It is described as a growing market that is forecast to expand from around US$48.4 billion this year to over US$91 billion by 2030.

https://www.proactiveinvestors.co.uk/companies/news/1025339/graft-polymer-inks-new-r-d-partnership-for-recycled-packaging-products-1025339.html

Graft Polymer (UK) PLC has signed a research and development and supply agreement with Empresas Vilher, a Mexican company that specialises in wood plastic composite, plastic recycling and high-performance compounds.

Work has been underway with a technical team from Vilher for several months on a variety of modified polymer projects, Graft Polymer added, and this has led to a formal 12-month R&D and supply agreement.

Wood plastic composite (WPC) is made from waste wood bonded together with a binding agent, where Graft believes its GRAFTABOND product leads the field in trials in several polymer matrices.

https://www.proactiveinvestors.co.uk/companies/news/1024925/graft-polymer-formalises-tie-up-with-mexican-recycling-specialist-1024925.html

Graft Polymer (UK) PLC (LSE:GPL) independent non-executive director Alex Brooks speaks to Thomas Warner from Proactive after the polymer modification company announced the signing of a manufacturing agreement with an undisclosed Israeli pharmaceutical partner to produce a patented blood-clotting powder at its GraftBio facility in Slovenia.

The product, designed to stimulate blood coagulation, holds versatile applications in wound care and surgical procedures. Brooks explains that Graft Polymer’s expertise in polymer knowledge and complex manufacturing processes makes them a natural choice to produce the powder.

https://www.proactiveinvestors.co.uk/companies/news/1024364/graft-polymer-eager-to-push-on-after-signing-fresh-manufacturing-agreement-1024364.html

Graft Polymer (UK) PLC, a chemicals firm specialising in modified polymer solutions, has entered a manufacturing agreement with an undisclosed Israeli pharmaceutical partner.

Under the terms of the deal, Graft will act as the lead contract manufacturing organisation, producing a patented blood-clotting powder at its GraftBio facility in Slovenia.

https://www.proactiveinvestors.co.uk/companies/news/1024323/graft-polymer-inks-deal-to-manufacture-blood-clotting-products-in-slovenia-1024323.html

Graft Polymer remains confident in the outlook for 2023, based on a healthy pipeline and scope for
harnessing enlarged operations to win larger customer mandates. The Company’s enlarged scale
following the completion of the Slovenian plant will drive greater cashflow generation to the benefit of
shareholders.

Today Alex Brooks joins Flagstaff TV to explain more about the company and give the latest updates.

Brooks goes on to talk about what’s been achieved so far in 2023, adding that he “remains optimistic that market conditions are getting better” and expects another year of strong revenue growth.

https://www.proactiveinvestors.co.uk/companies/news/1013658/graft-polymer-records-year-of-growth-against-somewhat-challenging-backdrop-1013658.html

Graft Polymer said it will begin production immediately on the US$1mln order for an anti-inflammatory supplement that will be sold in the US market.

https://www.proactiveinvestors.co.uk/companies/news/990599/graft-polymer-hails-the-first-order-in-the-us-market-for-graftbio-division-990599.html

GraftBio division has been granted a Hazard Analysis and Critical Control Point (“HACCP”) certificate at the Group’s Research and Development facility in Slovenia.

The grant of this certificate is a major milestone for Graft Polymer which will enable us to enter the Business-to-Consumer market.

Graft Polymer (UK) Plc (LSE: GPL), Established in 2017 by a group of polymer technology experts and venture capitalists, Graft Polymer’s core business comprises polymer modification and the development of drug delivery systems. The Group is a highly innovative business with strong intellectual property holding a solid Know-How Portfolio and several Patents.

Our motto: Combine the Incompatible vividly explained our business essence, namely the use of diverse modification technologies to combine variously immiscible and incompatible components of a polymer composite.

The Group has a wide spectrum of proprietary polymer modification technologies and developed more than 50 grades in its Product Pipeline, which can improve existing products by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes Bio Supplements and drug delivery systems to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic.

We are delighted to announce our public listing on the London Stock Exchanges’ Main Market – the market’s first IPO of 2022.

We have successfully fundraised £5 million to fund accelerated growth, expand the Group’s research and production facility in Slovenia to meet rising customer demand, upgrade existing facilities to enable future IP registration, and increase both inventory and marketing opportunities following expected increased sales.

The London market represents the greatest opportunity to take advantage of a broad and diverse pool of capital. Our CEO, Victor Bolduev, commented:

“Our admission to the LSE’s Main Market is an exciting milestone for Graft Polymer. The successful completion of our IPO represents the beginning of a new chapter as we look to develop new and innovative polymer modification technologies both in-house and in conjunction with key industry players and customers.

Graft Polymer’s listing will provide the Company with further capital to accelerate our development of intellectual property as well as new technologies to provide novel products and solutions for market challenges that arise. We believe the diversity of our products enables us to deliver to various industries highlighting the IPO as the first-of-its-kind in London.”

https://www.londonstockexchange.com/news-article/GPL/admission-to-main-market-first-day-of-dealings/15276319

Graft Polymer UK (Graft Polymer) has announced its intention to float on the London Stock Exchange.

The business will admit its shares to the official list of the Financial Conduct Authority, with the intention of trading on the main market for listed securities.

Graft Polymer specializes in the development of polymer modification and drug delivery systems and operates a research and marketing facility in Slovenia.

Established in 2017, the company has already introduced more than 50 products to the market.

The solutions and products offered by the group are designed to improve performance, reduce raw materials consumption, and enhance the physical values of finished products or improve their chemical interaction.

Graft Polymer has successfully submitted its patent application and was accepted by SIPO on the 28th of June 2021 (Patent Number: P-202100132).

Patent Application № SIPO P -202100132- Cannabinoids-Ionic complex self-nanoemulsifying concentrate and method for preparation thereof

The present disclosure relates to a Self-nanoemulsifying Cannabinoids-Ionic Complex concentrate, which consist of micellar mixture of three main phases, namely; Dispersion phase: (with at least one Cannabinoid and at least one Solvent, an Emulsifying phase: (with at least one Non-Ionic Surfactant, at least one Anionic Surfactant), and at least one “in situ” forming Ionic Complex, water and optionally other excipients and stabilizers.

The present disclosure relates to a method of manufacturing of Cannabinoids concentrate in liquid (oral mucosal spray, drops) or pharmaceutically acceptable solid (powder, gelatin capsule) forms.

We are pleased to announce our new product pipeline catalog.

For easier orientation, the products organized based on Graft Polymer trademarks split. Further information and more possibilities to search for certain products can be found on our products page.

https://graftpolymer.com/products-pipeline/

Environmental management has always been an essential part of our operations. Graft Polymer innovation polymer modification producer has been developed principles of sustainable development guide us in everything we do.

Adopting the ISO 14001:2015 standard for environmental management helps us to measure and improve our environmental impact even further.
In May 2021 GP received the ISO 14001:2015 Environmental Management Certification.

The international standard ISO 14001 sets out the requirements for an environmental management system and helps companies to identify, manage, monitor, and control their environmental impacts.

Following an extensive audit process, the certification was issued by BUREAU VERITAS, the world’s leading inspection, verification, testing, and certification company.

ISO 9001:2015 is a globally recognized standard dedicated to Quality Management Systems (QMS). It outlines a framework for improving quality and understanding for any organization looking to provide products and services that consistently meet the requirements and expectations of customers and other relevant interested parties in the most efficient manner possible.

Graft Polymer received the continued certification upon its annual external audit, showcasing the completeness and rigor of its data classification program.

Following an extensive audit process, the certification was issued by BUREAU VERITAS, the world’s leading inspection, verification, testing, and certification company.

Graft Polymer has successfully submitted its patent application and was accepted by SIPO on 19th of March 2021 (Patent Number: P-202100047).

Patent Application № P-202100047- Method for production of modified polyolefin.

The present invention relates to the production of modified polyolefin. The method of modified polyolefin production is described. It includes inoculation with non-saturated carboxylic acid or anhydride of non-saturated carboxylic acid on polyolefin by exposing shear strain from 50 to 1000% at 60-100°C, characterized in that preliminary ozonized polyolefin is used as polyolefin.

The technical result is an increase in the degree of grafting of the monomer, an increase in pureness and adhesive properties of the final product within saving the physical and mechanical properties of initial polymers.

Graft Polymer has successfully submitted its patent application and was accepted by SIPO on 16th March 2021 (Patent Number: P-202100044).

Patent Application № P-202100044- Method for industrial production of modified polymers and device for its realization.

The invention describes a method for industrial production of modified polymers in accordance with which a ground polymer undergoes gas-chemical modification in the fluidized state using reactive gases, including inert gases and ozone as a gaseous oxidizing agent and the obtained activated powder is mixed with a monomer or a group of monomers or a polymer, followed by their copolymerization through surface-initiated polymerization in a molten stage in an extruder.

The method is characterized by that gas-chemical modification is carried out at a temperature not higher than 30 °C and ozone concentration of 5-15 wt %, while blowing with reactive gases for 10-30 minutes, and polymerization in the extruder is carried out at 130- 230°C, while augers are rotating at 300-500 rpm, L/D of not less than 40, for the synthesis of graft and block copolymers with a degree of grafting of not less than 80%. The invention also describes a device for realizing said method.

Graft Polymer has successfully submitted its patent application and was accepted by Russian Patent Authority on 11th March 2021 (Patent Number: 2021106347).

Patent Application № P-2021106347- Super-saturable self-nano emulsifying drug delivery system (SNEDDS) for poorly water-soluble pharmaceutical compositions and method of its preparation.

The present invention provides an oral oil-free super-saturable self-nano emulsifying drug delivery system (SNEDDS) for pharmaceutical compositions of hydrophobic natural Active Pharmaceutical Ingredients (API), emulsifiers/co-solvents, and stabilized aqueous phase. The SNEDDS of the present invention shows an enhanced drug loading ability, self-emulsification, better stability, and improved bioavailability. The methods for preparing the oral super saturable self-nano emulsifying pharmaceutical compositions in liquid and solid forms are also provided.

Graft Polymer has successfully submitted its patent application and was accepted by SIPO on 22nd February 2021 (Patent Number: P-202100024).

Patent Application № P-202100024- Super-saturable self-nano emulsifying drug delivery system (SNEDDS) for poorly water-soluble pharmaceutical compositions and method of its preparation.

The present invention provides an oral oil-free super-saturable self-nano emulsifying drug delivery system (SNEDDS) for pharmaceutical compositions of hydrophobic natural Active Pharmaceutical Ingredients (API), emulsifiers/co-solvents, and stabilized aqueous phase. The SNEDDS of the present invention shows an enhanced drug loading ability, self-emulsification, better stability, and improved bioavailability. The methods for preparing the oral super saturable self-nano emulsifying pharmaceutical compositions in liquid and solid forms are also provided.